Regeneron and Sanofi announced FDA approval of Dupixent (dupilumab) for bullous pemphigoid (BP) in adults. This approval is based on positive Phase 2/3 trial results demonstrating improvements in sustained disease remission, itch reduction, and reduced oral corticosteroid use compared to placebo. BP, a chronic, relapsing skin disease characterized by painful blisters and intense itching, affects approximately 27,000 adults in the U.S.
This approval is a significant advancement for patients suffering from BP, primarily elderly individuals, who often face limited treatment options with potentially burdensome side effects. Dupixent offers a novel, targeted approach to managing the disease, potentially improving quality of life by addressing the underlying type 2 inflammation driving the condition. The potential for sustained remission offers hope for long-term disease control and a reduction in reliance on corticosteroids, minimizing their associated risks.
The pivotal trial showed that 18.3% of Dupixent-treated patients achieved sustained disease remission at 36 weeks versus 6.1% in the placebo group. Additionally, 38.3% experienced clinically meaningful itch reduction compared to 10.5% in the placebo arm. The median cumulative oral corticosteroid dose was also lower in the Dupixent group (2.8 grams) compared to placebo (4.1 grams). The most common adverse events in the Dupixent group were arthralgia, conjunctivitis, blurred vision, herpes viral infections, and keratitis.
This FDA approval expands Dupixent’s applicability to eight distinct diseases with underlying type 2 inflammation, strengthening its position as a versatile treatment across a range of conditions. It underscores the potential of targeting the IL-4 and IL-13 pathways in treating inflammatory diseases. Further, it paves the way for potential approvals in other regions and reinforces the growing importance of targeted therapies in dermatology. This could lead to the development of further targeted therapies for BP and similar conditions, potentially improving outcomes and reducing the reliance on broad immunosuppressants.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
